The securities will be offered by means of a prospectus supplement and accompanying prospectus relating to the offering that form a part of the registration statement. 333-235887) previously filed with the Securities and Exchange Commission (“SEC”) on January 10, 2020, which registration statement was declared effective on January 31, 2020. The securities described above are being offered by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. The Company intends to use the net proceeds of the offering for working capital and general corporate purposes.
Guggenheim Securities is acting as sole book-running manager for the offering. In addition, the Company intends to grant the underwriters a thirty-day option to purchase up to an additional 15 percent of shares of its common stock offered in the public offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares to be sold in the offering will be offered by the Company. (the “Company”, NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. NASHUA, N.H., Ma(GLOBE NEWSWIRE) - iCAD, Inc.
0 kommentar(er)
